Cure8 research brief
New PET tracers like FAPI could better detect fibrosis and stromal activity than standard FDG-PET, which may improve imaging of fibrostenotic Crohn's disease. For people with IBD, improved imaging might eventually help distinguish inflammatory from fibrotic disease and guide treatment or surgical decisions.
Gastroenterologists and radiologists who manage IBD imaging, researchers studying IBD imaging biomarkers and fibrosis, and patients with Crohn's disease or suspected fibrostenotic disease interested in advanced imaging options.
This abstract reports a systematic review and exploratory meta-analysis comparing fibroblast activation protein inhibitor (FAPI) PET/CT against 18F-FDG PET/CT for imaging in inflammatory bowel disease (IBD).
The authors pooled segment-level diagnostic data from a subset of studies and found that FAPI-PET showed descriptively higher sensitivity, specificity, accuracy, and diagnostic odds ratio than FDG-PET. Evidence was strongest for Crohn's disease and fibrostenotic disease; direct comparative data for ulcerative colitis were limited.
The review uses endoscopy-referenced cohorts where possible but notes patient-level pooled estimates could not be generated due to inconsistent reporting. FAPI-PET is presented as a promising modality particularly where fibrosis and stromal remodeling are relevant. For ulcerative colitis, the authors stress sparse direct comparative evidence.
The brief is grounded in the article abstract provided and does not reflect review of the full manuscript beyond that abstract.
This classification and note are based on the article abstract (structured content depth: abstract). The review highlights limited direct comparative data for ulcerative colitis and inconsistent patient-level reporting across studies, so findings are exploratory and hypothesis-generating rather than definitive.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Risk stratification helps identify people with Crohn's who are more likely to develop strictures, fistulas, or need surgery so clinicians can monitor and treat them more aggressively early on. Objective tests like fecal...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
